We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.1%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.9B
AUM Growth
+$737M
Cap. Flow
-$219M
Cap. Flow %
-1.29%
Top 10 Hldgs %
56.42%
Holding
122
New
26
Increased
36
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
ESRX
Express Scripts Holding Company
ESRX
+$353M
2
EQIX icon
Equinix
EQIX
+$266M
3
BKNG icon
Booking.com
BKNG
+$252M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$203M
5
AABA
Altaba Inc
AABA
+$162M

Top Sells

Rank Stock Value
1
KDP icon
Keurig Dr Pepper
KDP
+$596M
2
XL
XL Group Ltd.
XL
+$407M
3
LOGM
LogMein, Inc.
LOGM
+$214M
4
GILD icon
Gilead Sciences
GILD
+$207M
5
IQV icon
IQVIA
IQV
+$126M

Sector Composition

Rank Sector Weight
1 Healthcare 24.15%
2 Technology 17.4%
3 Communication Services 12.66%
4 Financials 12.19%
5 Industrials 5.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
51
CRISPR Therapeutics
CRSP
$4.99B
$45.2M 0.27%
1,018,594
+157,894
+18% +$8.27M
MRTX
52
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.2M 0.24%
875,000
+131,500
+18% +$7.32M
GRFS
53
Grifois
GRFS
$5.33B
$38.3M 0.23%
1,790,000
+1,238,696
+225% +$26.1M
RC
54
Ready Capital
RC
$279M
$36.7M 0.22%
2,203,239
-5,000
-0.2% -$83.6K
RDUS
55
DELISTED
Radius Health, Inc.
RDUS
$36.4M 0.21%
2,043,149
-2,043,151
-50% -$46.2M
SRPT icon
56
Sarepta Therapeutics
SRPT
$1.77B
$31.5M 0.19%
+195,000
New +$26.7M
IDTI
57
DELISTED
Integrated Device Technology I
IDTI
$30.1M 0.18%
+640,000
New +$24.7M
SVRA icon
58
Savara
SVRA
$1.19B
$27M 0.16%
2,418,009
+193,009
+9% +$2.22M
BUD icon
59
AB InBev
BUD
$165B
$25.7M 0.15%
293,109
-65,424
-18% -$6.38M
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$28.9B
$24.2M 0.14%
276,551
-138,449
-33% -$13.9M
TECX
61
Tectonic Therapeutic
TECX
$570M
$24.1M 0.14%
38,750
+9,300
+32% +$4.12M
PTGX icon
62
Protagonist Therapeutics
PTGX
$9.4B
$23.1M 0.14%
2,243,202
+1,332,973
+146% +$11.5M
PGNX
63
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$22.7M 0.13%
3,612,820
+961,720
+36% +$7.39M
ZYME icon
64
Zymeworks
ZYME
$1.7B
$21M 0.12%
1,335,000
+580,000
+77% +$8.3M
PTCT icon
65
PTC Therapeutics
PTCT
$5.91B
$19.7M 0.12%
+420,000
New +$17.4M
APTX
66
DELISTED
Aptinyx Inc. Common Stock
APTX
$19.4M 0.11%
670,000
+73,200
+12% +$1.78M
EXEL icon
67
Exelixis
EXEL
$13.1B
$19.1M 0.11%
+1,080,000
New +$21.1M
LRMR icon
68
Larimar Therapeutics
LRMR
$436M
$19M 0.11%
135,417
+29,872
+28% +$3.63M
PBYI icon
69
Puma Biotechnology
PBYI
$413M
$18.8M 0.11%
+410,000
New +$19.8M
VYGR icon
70
Voyager Therapeutics
VYGR
$189M
$17.2M 0.1%
909,158
+141,001
+18% +$2.71M
CDXS icon
71
Codexis
CDXS
$159M
$17.1M 0.1%
1,000,000
-125,000
-11% -$2.02M
BPY
72
DELISTED
Brookfield Property Partners L.P. Limited Partnership Units
BPY
$16.6M 0.1%
+794,382
New +$15.9M
SHPG
73
DELISTED
Shire pic
SHPG
$15.8M 0.09%
87,000
+17,453
+25% +$3.02M
NTLA icon
74
Intellia Therapeutics
NTLA
$1.57B
$15.7M 0.09%
550,000
-290,000
-35% -$8.44M
ZEAL
75
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$14.9M 0.09%
900,000
– –
1 2
3
4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Farallon Capital Management held 122 positions worth $16.9B, up 4.6% from $16.2B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Farallon Capital Management's Q3 2018 filing shows 26 new, 36 increased, 29 reduced and 20 closed positions. Its largest new stake was Equinix: 608,600 shares worth $263M. The largest sale was Keurig Dr Pepper, an estimated $596M.

By sector, the portfolio is most concentrated in Healthcare at 24% of assets, up from 20% a quarter earlier, followed by Technology and Communication Services.

  • Farallon Capital Management's largest Q3 2018 buy was Equinix: 608,600 shares worth $263M.
  • Farallon Capital Management added most to Express Scripts Holding Company in Q3 2018, an estimated $353M increase.
  • Farallon Capital Management's biggest Q3 2018 reduction was IQVIA, cutting an estimated $126M.
  • Farallon Capital Management fully exited Keurig Dr Pepper in Q3 2018, selling an estimated $596M.
  • Farallon Capital Management's ten largest holdings make up 56% of its $16.9B portfolio in Q3 2018.
  • Farallon Capital Management opened 26 new positions and closed 20 in Q3 2018.
  • Farallon Capital Management's portfolio value rose 4.6% quarter-over-quarter to $16.9B.

Based on Farallon Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.